Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Latest Research

Approved by the Cancer.Net Editorial Board, 08/2020

ON THIS PAGE: You will read about the scientific research being done to learn more about Waldenstrom macroglobulinemia and how to treat it. Use the menu to see other pages.

Doctors are working to learn more about Waldenstrom macroglobulinemia, ways to prevent it, how to best treat it, and how to provide the best care to people diagnosed with this disease. The following areas of research may include new options for patients through clinical trials. Always talk with your doctor about the best diagnostic and treatment options for you.

New treatments and targeted therapies. As explained in Types of Treatment, targeted therapy can block tumor growth in different ways. Other drugs that target how B cells develop are also being studied for the treatment of Waldenstrom macroglobulinemia. Several drugs that inhibit PI3 kinase are being evaluated for many B-cell cancers, including Waldenstrom macroglobulinemia. Everolimus (Afinitor), temsirolimus (Torisel), and drugs called histone deacetylase (HDAC) inhibitors, such as panobinostat (Farydak), are also being studied for Waldenstrom macroglobulinemia.

Drug combinations. Drugs are being used in combination to treat Waldenstrom macroglobulinemia:

  • Targeted therapies, such as rituximab, combined with chemotherapy are being studied as a way to eliminate more cancer cells.

    The drug fludarabine combined with cyclophosphamide is sometimes used to treat advanced and/or symptomatic Waldenstrom macroglobulinemia. Thalidomide (Thalomid) or lenalidomide (Revlimid) plus rituximab is also used. Another combination of drugs used is called DTPACE. This contains the following drugs:

    • Cisplatin (available as a generic drug)

    • Dexamethasone (multiple brand names)

    • Doxorubicin (available as a generic drug)

    • Cyclophosphamide

    • Etoposide (Etopophos)

  • Bortezomib, dexamethasone, and rituximab recently have been shown to be an active combination to treat Waldenstrom macroglobulinemia.

Palliative care/supportive care. Clinical trials are underway to find better ways of reducing symptoms and side effects of current Waldenstrom macroglobulinemia treatments to improve comfort and quality of life for patients.

Looking for More about the Latest Research?

If you would like additional information about the latest areas of research regarding Waldenstrom macroglobulinemia, explore these related items that take you outside of this guide:

The next section in this guide is Coping with Treatment. It offers some guidance on how to cope with the physical, emotional, social, and financial changes that cancer and its treatment can bring. Use the menu to choose a different section to read in this guide.